Navigation Links
Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis
Date:3/26/2008

Forms One of the Largest Sales Teams Promoting a 5-ASA Medicine

BASINGSTOKE, England and PHILADELPHIA, March 26 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today a co-promotion agreement with TAP Pharmaceutical Products Inc. for LIALDA(TM) (mesalamine) with MMX(R) technology, indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis (UC). This three year agreement is for the U.S. only and will add more than 500 additional sales representatives from TAP to increase the reach and frequency of the Shire sales force, which consists of 120 representatives who are currently detailing LIALDA primarily to gastroenterologists.

"Aligning with TAP, one of the most successful and well-respected GI sales organizations in the industry, is a tremendous benefit for Shire as it will quadruple the Lialda sales force across the United States," said Mike Yasick, senior vice president of Shire's Gastrointestinal Business Unit. "With the added expertise of the TAP team, we'll be able to reach more GI specialists as well as primary care providers with messages about Lialda. Shire's GI team has made Lialda the fastest growing brand of mesalamine and with this collaboration we will bolster the frequency of sales calls to our existing base of specialist physicians."

LIALDA is the first and only FDA-approved once-daily oral formulation of mesalamine indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis. Mesalamines are a part of a drug class called aminosalicylates, which contain 5-aminosalicyclic acid (5-ASA), a well-established drug of choice and often a first-line treatment for patients with mild to moderate ulcerative colitis.

"Building on the successful introduction of Lialda, which Shire launched in the first quarter of last year, we are excited to work with the Shire team as together
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
11. Shire Engages Palio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... , Mar. 03, 2015 Research and Markets ... of Jain PharmaBiotech,s new report "RNAi - Technologies, ... Because of its ability to silence any ... adopted as the research tool to discriminate gene function. ... can be designed to target every gene in the ...
(Date:3/3/2015)... Elsevier,s DirectCourse online curricula provides states ... comply with new CMS requirements   ... crosswalk tool to help providers of Home and ... workers as a means to comply with new Centers ... CMS amended the regulations, effective March 17, 2015, to ...
(Date:3/3/2015)... - BioAmber Inc. (NYSE: BIOA ), an ... has initiated commissioning activities for its 30,000 MT capacity ... , Canada.  Commissioning and start-up ... facility being in commercial operation in Q3 2015.  The ... and it is carrying out commissioning and start-up activities ...
(Date:3/3/2015)... -- Phillip Sharp, Institute Professor at the Massachusetts Institute of Technology ... the Koch Institute for Integrative Cancer Research, will receive the ... May 14, at the Chemical Heritage Foundation. Sharp is ... it was first awarded to Ralph Landau ... gave the scientific world a new view of the ...
Breaking Biology Technology:Global RNAi Market Report 2015 - Technologies, Markets and Companies 2014-2024 2Global RNAi Market Report 2015 - Technologies, Markets and Companies 2014-2024 3Elsevier's DirectCourse Can Help States Meet and Exceed New CMS Requirements for Home and Community-Based Services 2Elsevier's DirectCourse Can Help States Meet and Exceed New CMS Requirements for Home and Community-Based Services 3BioAmber Begins Commissioning of Sarnia Commercial Plant 2BioAmber Begins Commissioning of Sarnia Commercial Plant 3Phillip Sharp to Receive 2015 Othmer Gold Medal 2Phillip Sharp to Receive 2015 Othmer Gold Medal 3
... Aug. 2, 2011 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ... six months ended June 30, 2011. For the ... $21.5 million, or $0.37 per basic and diluted share, compared ... $0.51 per basic and diluted share, respectively, in the same ...
... ITHACA, N.Y. Every year, millions of people contend ... ease their pain, Cornell University engineers in Ithaca and ... York City have created a biologically based spinal implant ... Lawrence Bonassar, Ph.D., associate professor of biomedical ...
... Research Council (BBSRC) have taken a step towards producing ... livestock - after successfully assembling the virus outside a ... the journal Proceedings of the National Academy of ... develop vaccines with useful new properties. Professor Polly ...
Cached Biology Technology:Rigel Announces Second Quarter 2011 Financial Results 2Rigel Announces Second Quarter 2011 Financial Results 3Rigel Announces Second Quarter 2011 Financial Results 4Rigel Announces Second Quarter 2011 Financial Results 5In the battle to relieve back aches, Cornell researchers create bioengineered spinal disc implants 2In the battle to relieve back aches, Cornell researchers create bioengineered spinal disc implants 3Scientists take a step towards developing better vaccines for bluetongue 2Scientists take a step towards developing better vaccines for bluetongue 3
(Date:2/23/2015)... Conn. , Feb. 23, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... has filed provisional patent 62114357 for DISTRIBUTED ... this patent, NXT-ID introduces a new groundbreaking payment method. ... the payment account may only be accessed if both ...
(Date:2/13/2015)... -- ACT Genomics Co., Ltd., a cancer molecular ... genomic information into precision diagnosis and personalized treatments, ... million in the its first private funding round. ... , ACT Genomics has developed comprehensive cancer ... implement next generation sequencing (NGS) and multiplex molecular ...
(Date:2/11/2015)... DALLAS , February 11, 2015 /PRNewswire/ ... market research report "Access Control Market by Product ... (Commercial, Residential, Military and Defense, Government, Industrial, Healthcare, ... , published by MarketsandMarkets, the Access Control ... by 2020, growing at a CAGR of ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3ACT Genomics Raises $8 Million in its First Private Funding Round 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4
... has concluded that small mammals, such as rabbits and ... natural diversity. Smit researched how scrub becomes established in ... in protecting plants and preventing animal species from grazing. ... flooding and animal diseases are very important for the ...
... Want to slow the signs of aging and live ... calories could be a promising strategy. Calorie restriction ... rats and mice. While scientists do not know how calorie ... is that it slows aging by decreasing a thyroid hormone, ...
... 2008 Endangered wild orangutan (Pongo spp.) populations are ... estimated, according to new findings published this month by ... and other orangutan conservation experts in Oryx ... essential to survival of orangutans, found only on the ...
Cached Biology News:Tasty meal out of reach 2Looking for the Founatain of Youth? Cut your calories, research suggests 2Great Ape Trust's Wich lead author of Oryx paper on continuing orangutan population declines 2Great Ape Trust's Wich lead author of Oryx paper on continuing orangutan population declines 3Great Ape Trust's Wich lead author of Oryx paper on continuing orangutan population declines 4Great Ape Trust's Wich lead author of Oryx paper on continuing orangutan population declines 5
... Nutating Mixer is a combination of an ... three dimensional action while providing gentle, thorough ... unit can be used for a variety ... specimens, tissue culture, immunoblots, staining/destaining, chromatography, etc. ...
... GenElute™ Agarose Spin Columns are designed for the ... kb DNA from agarose gels. The DNA band ... the spin column. Embedded within the base of ... filters that hold agarose and impurities back while ...
...
... The Synaptic Vesicles Isolation Kit provides ... an enriched synaptic vesicle fraction. The ... lysis of the synaptosomes, and differential ... gradient. The kit also contains an ...
Biology Products: